Binding Interactions of Dopamine and Apomorphine in D2High and D2Low States of Human Dopamine D2 Receptor Using Computational and Experimental Techniques

ACS Chemical Neuroscience

Volumn 7, Issue 2, 2016, Pages 185-195

  Durdagi, Serdar ^a   Salmas, Ramin Ekhteiari ^a,b   Stein, Matthias ^c   Yurtsever, Mine ^b   Seeman, Philip ^d  

^a BAHCESEHIR UNIVERSITY   (Turkey)

^b ISTANBUL TECHNICAL UNIVERSITY   (Turkey)

^c MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

D2High and D2Low states of dopamine; Dopamine D2 receptor; GPCR dimerization; molecular docking; protein engineering

Indexed keywords

APOMORPHINE; DIMER; DOPAMINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; MONOMER; DOPAMINE RECEPTOR STIMULATING AGENT; PROTEIN BINDING;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DIMERIZATION; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG RECEPTOR BINDING; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STEREOSPECIFICITY; THREE DIMENSIONAL IMAGING; BINDING COMPETITION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR MODEL; PROCEDURES;

APOMORPHINE; BINDING, COMPETITIVE; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, DOPAMINE D2;

EID: 84959354684     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00271     Document Type: Article

References (51)

1. Audet, M. And Bouvier, M. (2012) Restructuring G-Protein- Coupled Receptor Activation Cell 151, 14-23 10.1016/j.cell.2012.09.003
2. Dror, R. O., Arlow, D. H., Maragakis, P., Mildorf, T. J., Pan, A. C., Xu, H., Borhani, D. W., and Shaw, D. E. (2011) Activation mechanism of the β2 -adrenergic receptor Proc. Natl. Acad. Sci. U. S. A. 108, 18684-18689 10.1073/pnas.1110499108
3. Rosenbaum, D. M., Zhang, C., Lyons, J. A, Holl, R., Aragao, D., Arlow, D. H., Rasmussen, S. G. F., Choi, H.-J., Devree, B. T., Sunahara, R. K., Chae, P. S., Gellman, S. H., Dror, R. O., Shaw, D. E., Weis, W. I., Caffrey, M., Gmeiner, P., and Kobilka, B. K. (2011) Structure and function of an irreversible agonist-β(2) adrenoceptor complex Nature 469, 236-240 10.1038/nature09665
4. McDonald, W. M., Sibley, D. R., Kilpatrick, B. F., and Caron, M. G. (1984) Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors Mol. Cell. Endocrinol. 36, 201-9 10.1016/0303-7207(84)90037-6
5. George, S. R., Watanabe, M., Di Paolo, T., Falardeau, P., Labrie, F., and Seeman, P. (1985) The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form Endocrinology 117, 690-697 10.1210/endo-117-2-690
6. Seeman, P. (2007) Antiparkinson therapeutic potencies correlate with their affinities at dopamine D2High receptors Synapse 61, 1013-1018 10.1002/syn.20453
7. Seeman, P., Ulpian, C., Wreggett, K. A, and Wells, J. W. (1984) Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: Analysis and examples J. Neurochem. 43, 221-35 10.1111/j.1471-4159.1984.tb06700.x
8. Seeman, P. And Van Tol, H. H. (1995) Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand Eur. J. Pharmacol., Mol. Pharmacol. Sect. 291, 59-66 10.1016/0922-4106(95)90125-6
9. Seeman, P., Watanabe, M., Grigoriadis, D., Tedesco, J. L., George, S. R., Svensson, U., Nilsson, J. L. G., and Neumeyer, J. L. (1985) Dopamine D2 receptor binding sites for agonists. A tetrahedral model Mol. Pharmacol. 28, 391-399
10. Seeman, P., Tallerico, T., and Ko, F. (2003) Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography Synapse 49, 209-15 10.1002/syn.10232
11. Seeman, P., Weinshenker, D., Quirion, R., Srivastava, L. K., Bhardwaj, S. K., Grandy, D. K., Premont, R. T., Sotnikova, T. D., Boksa, P., El-Ghundi, M., O'Dowd, B. F., George, S. R., Perreault, M. L., Männistö, P. T., Robinson, S., Palmiter, R. D., and Tallerico, T. (2005) Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis Proc. Natl. Acad. Sci. U. S. A. 102, 3513-3518 10.1073/pnas.0409766102
12. Seeman, P., Schwarz, J., Chen, J. F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., Yanai, K., Weinshenker, D., and Sumiyoshi, T. (2006) Psychosis pathways converge via D2High dopamine receptors Synapse 60, 319-46 10.1002/syn.20303
13. Han, Y., Moreira, I. S., Urizar, E., Weinstein, H., and Javitch, J. A. (2009) Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation Nat. Chem. Biol. 5, 688-695 10.1038/nchembio.199
14. Wang, M., Pei, L., Fletcher, P. J., Kapur, S., Seeman, P., and Liu, F. (2010) Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization Mol. Brain 3, 25 10.1186/1756-6606-3-25
15. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. (1993) PROCHECK: A program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26, 283-291 10.1107/S0021889892009944
16. Gopalakrishnan, K., Sowmiya, G., Sheik, S. S., and Sekar, K. (2007) Ramachandran plot on the web (2.0) Protein Pept. Lett. 14, 669-671 10.2174/092986607781483912
17. Roberts, D. J. And Strange, P. G. (2005) Mechanisms of inverse agonist action at D2 dopamine receptors Br. J. Pharmacol. 145, 34-42 10.1038/sj.bjp.0706073
18. Guo, W., Shi, L., and Javitch, J. A. (2003) The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer J. Biol. Chem. 278, 4385-8 10.1074/jbc.C200679200
19. Castro, S. W. And Strange, P. G. (1993) Differences in the Ligand Binding Properties of the Short and Long Versions of the D2 Dopamine Receptor J. Neurochem. 60, 372-375 10.1111/j.1471-4159.1993.tb05863.x
20. Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D. A, Engel, A., and Palczewski, K. (2003) Atomic-force microscopy: Rhodopsin dimers in native disc membranes Nature 421, 127-128 10.1038/421127a
21. Guo, W., Shi, L., Filizola, M., Weinstein, H., and Javitch, J. A. (2005) Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation Proc. Natl. Acad. Sci. U. S. A. 102, 17495-17500 10.1073/pnas.0508950102
22. Lee, S. P., O'Dowd, B. F., Rajaram, R. D., Nguyen, T., and George, S. R. (2003) D2 dopamine receptor homodimerization is mediated by multiple sites of interaction, including an intermolecular interaction involving transmembrane domain 4 Biochemistry 42, 11023-11031 10.1021/bi0345539
23. Armstrong, D. And Strange, P. G. (2001) Dopamine D2 receptor dimer formation: evidence from ligand binding J. Biol. Chem. 276, 22621-22629 10.1074/jbc.M006936200
24. Cheng, Y. And Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22, 3099-3108 10.1016/0006-2952(73)90196-2
25. Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T. A, Lyons, J. A, Caffrey, M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K., and Kobilka, B. K. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex Nature 477, 549-55 10.1038/nature10361
26. Hanson, M. A., Cherezov, V., Griffith, M. T., Roth, C. B., Jaakola, V.-P., Chien, E. Y. T., Velasquez, J., Kuhn, P., and Stevens, R. C. (2008) A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor Structure 16, 897-905 10.1016/j.str.2008.05.001
27. Boutet, E., Lieberherr, D., Tognolli, M., Schneider, M., and Bairoch, A. (2007) UniProtKB/Swiss-Prot Methods Mol. Biol. 406, 89-112 10.1007/978-1-59745-535-0-4
28. Salmas, R. E., Yurtsever, M., Stein, M., and Durdagi, S. (2015) Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions Mol. Diversity 19, 321-32 10.1007/s11030-015-9569-3
29. Eswar, N., Webb, B., Marti-Renom, M. A, Madhusudhan, M. S., Eramian, D., Shen, M.-Y., Pieper, U., and Sali, A. (2007) Comparative protein structure modeling using MODELLER Curr. Protoc. Protein Sci. 10.1002/0471140864.ps0209s50
30. Das, R. And Baker, D. (2008) Macromolecular modeling with rosetta Annu. Rev. Biochem. 77, 363-382 10.1146/annurev.biochem.77.062906.171838
31. Bas, D. C., Rogers, D. M., and Jensen, J. H. (2008) Very fast prediction and rationalization of pKa values for protein-ligand complexes Proteins: Struct., Funct., Genet. 73, 765-783 10.1002/prot.22102
32. Fotiadis, D., Jastrzebska, B., Philippsen, A., Müller, D. J., Palczewski, K., and Engel, A. (2006) Structure of the rhodopsin dimer: A working model for G-protein-coupled receptors Curr. Opin. Struct. Biol. 16, 252-9 10.1016/j.sbi.2006.03.013
33. Salmas, R. E., Yurtsever, M., and Durdagi, S. (2015) Investigation of Inhibition Mechanism of Chemokine Receptor CCR5 by Micro-second Molecular Dynamics Simulations Sci. Rep. 5, 13180 10.1038/srep13180
34. Leonis, G., Avramopoulos, A., Salmas, R. E., Durdagi, S., Yurtsever, M., and Papadopoulos, M. G. (2014) Elucidation of conformational states, dynamics, and mechanism of binding in human κ-opioid receptor complexes J. Chem. Inf. Model. 54, 2294-308 10.1021/ci5002873
35. Durdagi, S., Papadopoulos, M. G., Zoumpoulakis, P. G., Koukoulitsa, C., and Mavromoustakos, T. (2010) A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: Homology modeling, docking, de novo drug design and molecular dynamics analysis Mol. Diversity 14, 257-276 10.1007/s11030-009-9166-4
36. Potamitis, C., Zervou, M., Katsiaras, V., Zoumpoulakis, P., Durdagi, S., Papadopoulos, M. G., Hayes, J. M., Grdadolnik, S. G., Kyrikou, I., Argyropoulos, D., Vatougia, G., and Mavromoustakos, T. (2009) Antihypertensive drug valsartan in solution and at the AT1 receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations J. Chem. Inf. Model. 49, 726-39 10.1021/ci800427s
37. Durdagi, S., Kapou, A., Kourouli, T., Andreou, T., Nikas, S. P., Nahmias, V. R., Papahatjis, D. P., Papadopoulos, M. G., and Mavromoustakos, T. (2007) The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1′ position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2 J. Med. Chem. 50, 2875-85 10.1021/jm0610705
38. Agelis, G., Resvani, A., Durdagi, S., Spyridaki, K., Tůmová, T., Slaninová, J., Giannopoulos, P., Vlahakos, D., Liapakis, G., Mavromoustakos, T., and Matsoukas, J. (2012) The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: A concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives Eur. J. Med. Chem. 55, 358-74 10.1016/j.ejmech.2012.07.040
39. (2009) Desmond Molecular Dynamics System, version 2.2, D.E. Shaw Research, New York.
40. Siu, S. W. I., Pluhackova, K., and Böckmann, R. A. (2012) Optimization of the OPLS-AA force field for long hydrocarbons J. Chem. Theory Comput. 8, 1459-1470 10.1021/ct200908r
41. Essmann, U., Perera, L., Berkowitz, M. L., Darden, T., Lee, H., and Pedersen, L. G. (1995) A smooth particle mesh Ewald method J. Chem. Phys. 103, 8577-8593 10.1063/1.470117
42. Hoover, W. G. (1985) Canonical dynamics: Equilibrium phase-space distributions Phys. Rev. A: At., Mol., Opt. Phys. 31, 1695-1697 10.1103/PhysRevA.31.1695
43. Martyna, G. J., Tobias, D. J., and Klein, M. L. (1994) Constant pressure molecular dynamics algorithms J. Chem. Phys. 101, 4177 10.1063/1.467468
44. (2014) MacroModel, version 10.6, Schrödinger, LLC, New York.
45. (2014) LigPrep, version 3.2, Schrödinger, LLC, New York.
46. (2014) Maestro, version 10.0, Schrödinger, LLC, New York.
47. Farid, R., Day, T., Friesner, R. A., and Pearlstein, R. A. (2006) New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies Bioorg. Med. Chem. 14, 3160-3173 10.1016/j.bmc.2005.12.032
48. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Sanschagrin, P. C., and Mainz, D. T. (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 49, 6177-6196 10.1021/jm051256o
49. Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., and Friesner, R. A. (2004) A Hierarchical Approach to All-Atom Protein Loop Prediction Proteins: Struct., Funct., Genet. 55, 351-367 10.1002/prot.10613
50. Annamala, M. K., Inampudi, K. K., and Guruprasad, L. (2007) Docking of phosphonate and trehalose analog inhibitors into M. Tuberculosis mycolyltransferase Ag85C: Comparison of the two scoring fitness functions GoldScore and ChemScore, in the GOLD software Bioinformation 1, 339-50 10.6026/97320630001339
51. Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., and Taylor, R. D. (2003) Improved protein-ligand docking using GOLD Proteins: Struct., Funct., Genet. 52, 609-623 10.1002/prot.10465